Revised EQA timetable published
Our EQA scheme timetable was impacted by the COVID-19 pandemic. Please click the link below for the revised timetable (published 01.07.2020).
EMQN collaborates with QCMD to provide a pilot EQA scheme for coronaviruses (SARS-CoV-2)
Please visit the READ MORE link below to learn more about this initiative.
EMQN and GenQA collaborate to launch pilot EQA for advanced (metastatic) Prostate Cancer
Manchester, UK, 6th March 2020: EMQN CIC today announced it is collaborating with GenQA to launch a pilot EQA scheme for HRR gene testing in patients with advanced Prostate Cancer.
EMQN and GenQA collaborate to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer
Manchester, UK, 26th February 2020: EMQN CIC today announced it is collaborating with GenQA to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer.
We are a not-for-profit organisation promoting quality in genetic testing by establishing, harmonising and disseminating best practice.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
The latest news and press releases
2021 EQA scheme registration opens 1st October - https://t.co/5ZoEr2TdOH https://t.co/9HGFbk0FHX
Last call for registrations - round 2 of the Coronavirus Outbreak EQA scheme - https://t.co/Q4gnl3bYom
Our HRF scheme will become the SAID's EQA scheme in 2021 as we increase the scope to include other commonly tested… https://t.co/EtmO5L6RlM
Is your laboratory undertaking genomic testing of HRR gene(s) for prostate cancer? If you are, then you may be in… https://t.co/9CC5mvWRHQ
Is your laboratory undertaking genomic testing of HRR gene(s) in prostate cancer? If you are, then you may be inter… https://t.co/yh94A8JoO1